A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIMS: Oral semaglutide absorption is subject to inter-individual variability. We investigated whether estimated individual exposure (eC) provides predictive information beyond the prescribed dose in a real-world cohort of patients with type 2 diabete…
OBJECTIVES: This study aimed to identify key regulatory genes involved in chondrocyte senescence in osteoarthritis (OA) and to evaluate the therapeutic potential of the GLP-1 receptor agonist semaglutide. METHODS: Transcriptomic data of chondrocytes…
Individuals who carry two copies of the apolipoprotein E ε4 (ε4) allele are at high risk of developing Alzheimer's disease (AD), yet the effects ofε4 homozygosity on biological pathways related to AD over the lifespan are unknown. Here we analyzed th…
PURPOSE OF REVIEW: Obstetricians and gynecologists increasingly encounter patients using glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists. This review synthesizes evidence on these…
Cardiovascular disease (CVD) remains the leading cause of global mortality, with pathophysiological alterations such as heart failure with preserved ejection fraction, diabetic cardiomyopathy, and atherosclerotic cardiomyopathy representing major ris…
: Glucagon-like peptide-1 receptor agonists are increasingly prescribed for weight loss, but concerns remain regarding adverse events beyond gastrointestinal, renal, and pancreatic effects. Understanding these risks is essential to guide safe clinica…
BACKGROUND AND OBJECTIVE: Inflammation plays a central role in the pathophysiology of atherosclerosis and contributes to residual cardiovascular risk (CVR). High-sensitivity C-reactive protein (hs-CRP) and fibrinogen are considered key biomarkers in…
BACKGROUND AND OBJECTIVES: Recent observational studies have reported conflicting evidence regarding an association between glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly semaglutide, and nonarteritic anterior ischemic optic neuro…
INTRODUCTION: Within the cardiovascular-kidney-metabolic syndrome (CKM) framework, semaglutide has demonstrated benefits beyond glycemic control and weight loss in clinical trials. However, most real-world studies in type 2 diabetes (T2D) have limite…
PURPOSE: To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2026 in the United States, with a focus on the nonfederal hospital and clinic sec…
BACKGROUND: Both tirzepatide and semaglutide, once-weekly injectable incretin-based agents, have demonstrated substantial weight-reducing potential in populations with overweight or obesity. However, the relative effectiveness of these two agents rem…
AIM: To explore changes in body composition in adolescents with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RA) and their association with metabolic syndrome (MetS) components. METHODS: This real-world retrospective study inc…
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide (SEM) and tirzepatide (TZP) were initially approved for type 2 diabetes management but are increasingly used for weight loss. Limited data exist on real-world use am…
BACKGROUND: Medical societies shape clinical standards, develop practice guidelines, and provide continuing education to physicians. Many receive funding from pharmaceutical and medical device companies, creating conflicts of interest (COI); however,…
Salcaprozate sodium (SNAC) is an FDA GRAS-listed permeation enhancer used in oral semaglutide and vitamin B12 formulations. Although its rapid and reversible membrane-perturbing effects are well recognised, it's in vivo performance is highly variable…
A decline in mortality due to heart failure (HF) with reduced ejection fraction (HFrEF) has been attributed to effective guideline-directed medical therapies. But few effective therapies are available for HF with preserved ejection fraction (HFpEF),…
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist, exhibits significant neuroprotective effects in stroke and neurodegenerative diseases. However, the antiinflammatory and barrier-protective effects of semaglutide and the mechanisms…
INTRODUCTION: With new advancements in obesity medicine, clarity on goals and expectations for successful disease management is limited. This post hoc analysis assessed application of proposed treat-to-target (TtT) thresholds for obesity to the outco…
Ulcerative colitis (UC) often requires immunosuppressive therapy for remission. Glucagon-like peptide-1 receptor agonists are used for diabetes and obesity, although their role in UC is unclear. We report a 42-year-old woman with left-sided UC and po…